BridgeBio Pharma, Inc. (BBIO)

About BridgeBio Pharma, Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

As of November 3, 2026, BridgeBio Pharma, Inc. (BBIO) stock rose to $75.40, up 0.54% (+$0.40) versus the previous close. On the day, shares have traded between $75.25 and $76.79. That puts BBIO around the middle of its 52-week range of $60.22 to $93.42. BridgeBio Pharma, Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $14.60 billion, with about 829.4K shares changing hands.

Latest BBIO news

• BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026Yahoo Finance· Nov 3, 7:30 AM ET
• Recursion Appoints Fred Hassan as Chair of the BoardYahoo Finance· Nov 2, 4:05 PM ET
• Should You Invest $1,000 in BridgeBio Pharma Right Now?fool.com· Nov 2, 7:05 AM ET
• What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches?Yahoo Finance· Nov 1, 4:10 PM ET
• BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS SaysYahoo Finance· Oct 30, 1:04 PM ET
• BridgeBio (BBIO) Q3 2026 Earnings Call Transcriptfool.com· Oct 30, 10:29 AM ET
• BridgeBio Pharma, Inc. Q3 2026 Earnings Call Summaryapp.moby.co· Oct 30, 8:30 AM ET
• What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Callmarketbeat.com· Oct 29, 8:14 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want BBIO headlines, alerts and AI research in one place? Create a free account →

• $BBIO Company had a one time milestone payment in the sales fig. Even so, they did increase sales again for attruby. There are a few hidden pros here. They will surely get 3 approvals in the coming months. Data is super strong. Also they will be eligible for id say 3 PRVs a va…

  @LMXPERTEN· Nov 3, 3:17 AM ET· Bullish

• nov 27 is circled for $BBIO imo BBP 418 PDUFA for limb girdle muscular dystrophy type 2I, priority review in hand, no advisory committee planned, and if approved it would be the first therapy for any limb girdle form stock closed today near $75 after Q3 revenue jumped to about…

  @BiotechSwings· Nov 2, 7:19 PM ET

• $BBIO closed the week at $74.95 (+9.3% w/w, +6.0% Friday), above the 50-day SMA ($70.27) and above the 200-day ($72.74). RSI14 70.2. Support $62.86, resistance $75.85 (20-day range, top). Oct 29: Q3 revenue $353.2M, with U.S. Attruby net revenue of $253.2M; cash and securities…

  @Merlintrader· Nov 1, 8:26 AM ET

• $COGT $BBIO buying the dip will be greatly rewarded

  @CrispDry· Oct 31, 11:25 AM ET· Bullish

• Attruby did the heavy lifting again imo $BBIO closed Friday at 74.95, up about 6% from 70.73, after Q3 revenue jumped to about 353 million from about 121 million a year ago Attruby itself pulled about 253 million, up from last quarter, and the quarter beat on both revenue and …

  @BiotechSwings· Oct 31, 2:57 AM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →